Nine senators sent a letter to FTC Chairman Joseph Simons urging greater scrutiny over like the one between BMS and Celgene, expressing concern over antitrust issues, innovation and drug pricing.
In a letter to Federal Trade Commission Chairman Joseph Simons this week, the senators urged the agency to closely scrutinize mergers in the biopharma industry that raised issues around competition, especially as rising costs of prescription drugs have become a significant public policy issue.
Sen. Amy Klobuchar, D-Minnesota and ranking member of the Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights led the letter. Seven other Democratic senators – Richard Blumenthal of Connecticut, Cory Booker of New Jersey, Mazie Hirono of Hawaii, Kamala Harris of California, Elizabeth Warren of Massachusetts, Tammy Baldwin of Wisconsin, Tina Smith of Minnesota and independent Bernie Sanders of Vermont were also signatories. Klobuchar, Booker, Harris, Warren and Sanders are also running for president on the Democratic ticket.
“This industry consolidation is occurring against a backdrop of ever rising prescription drug spending and reports that one-in-four people taking prescription drugs have difficulty affording their medication,” the letter read. “It is more important than ever that the FTC take appropriate action to protect consumers.”
Full Content: Klobuchar
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI